FDA Approves Ertugliflozin for Type 2 Diabetes
The FDA has approved the sodium-glucose cotransporter-2 (SGLT2) inhibitor ertugliflozin as an adjunct to diet and exercise for treating adults with type 2...
Source: Physician's First Watch current issue - Category: Primary Care Source Type: news
More News: Diabetes | Diabetes Type 2 | Diets | Endocrinology | Nutrition | Primary Care | SGLT2 Inhibitors | Sodium | Sports Medicine